A Phase 1/2 Study to Evaluate MEDI4736

Status Completed

Clinical Trial Summary

This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in participants with advanced solid tumors followed by an expansion phase in participants with advanced solid tumors. An exploration cohort has been added to determine the safety using every 4 weeks (Q4W) dosing.

Clinical Trial Description

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death ligand-1 (PD-L1)) will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity (IM), and antitumor activity of MEDI4736 in adult participants with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736. ;

Study Design

Related Conditions & MeSH terms

Advanced Solid Tumors

Clinical Trial Details

NCT number	NCT01693562
Study type	Interventional
Source	MedImmune LLC
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 5, 2012
Completion date	February 28, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04972981` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT05086822` - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors	Phase 1
Completed	`NCT03260322` - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Recruiting	`NCT05862831` - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03641794` - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers	Phase 1
Terminated	`NCT03665129` - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06413680` - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies	Phase 1/Phase 2
Recruiting	`NCT05914116` - A Study of DB-1311 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04387916` - A Study of KC1036 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04095273` - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Phase 1
Not yet recruiting	`NCT03692520` - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02997176` - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)	Phase 1
Recruiting	`NCT04446260` - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06239155` - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT02253992` - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06076291` - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT03545971` - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.	Phase 1
Completed	`NCT00962091` - Study of MLN8237 in Participants With Advanced Solid Tumors	Phase 1